To address these limitations, future studies will need to include larger patient cohorts evaluated using more sensitive and specific methodologies (e.g., RNA-seq) along with comprehensive clinicopathological information and appropriate follow-up to enable analysis of the relationship between AR/ESR1 and AR/PGR ratios and survival parameters as well as BC progression. This evidence concerns the gene AR and breast cancer.